Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| TENAX THERAPEUTICS, INC.TENX · Entity 979 | Director | May 18, 2020 | May 19, 2020 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
TENAX THERAPEUTICS, INC.
Report date May 18, 2020 · Filed May 19, 2020
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 6,062 |
Reported balance
After 2020-05-18 transaction · row 1
1 source rowRow 1 · 2020-05-18 · Purchase · Acquired 5,000 · Balance 6,062 |
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| May 18, 2020 Filed May 19, 2020 20:31 UTC | TENAX THERAPEUTICS, INC. TENX · Entity 979 | PurchaseCommon Stock | 5,000 | $0.95 | $4,774.00 |
DisclosureSEC source: 0001654954-20-005765 · section16.xml · nonDerivative · entry 1 BLANCK RONALD R · CIK 0001252491 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,062 Read SEC document |
| May 01, 2020 Filed May 15, 2020 21:01 UTC | TENAX THERAPEUTICS, INC. TENX · Entity 979 | GrantStock Option (right to buy) · Derivative | 500 | $0.00 Strike: $0.66 | $0.00 |
DisclosureSEC source: 0001654954-20-005665 · section16.xml · derivative · entry 1 BLANCK RONALD R · CIK 0001252491 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 500 Underlying: Common Stock · 500 shares Expires 2030-05-01 Read SEC document |
| May 01, 2018 Filed Apr 18, 2019 20:31 UTC | TENAX THERAPEUTICS, INC. TENX · Entity 979 | GrantStock Option (right to buy) · Derivative | 500 | $0.00 Strike: $6.23 | $0.00 |
DisclosureSEC source: 0001654954-19-004581 · section16.xml · derivative · entry 1 BLANCK RONALD R · CIK 0001252491 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 500 Underlying: Common Stock · 500 shares Expires 2028-05-01 Read SEC document |
| December 18, 2017 Filed Dec 20, 2017 14:50 UTC | TENAX THERAPEUTICS, INC. TENX · Entity 979 | PurchaseCommon Stock | 6,475 | $0.45 | $2,881.38 |
DisclosureSEC source: 0001654954-17-011773 · section16.xml · nonDerivative · entry 2 BLANCK RONALD R · CIK 0001252491 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,099 Read SEC document |
| December 18, 2017 Filed Dec 20, 2017 14:50 UTC | TENAX THERAPEUTICS, INC. TENX · Entity 979 | PurchaseCommon Stock | 6,475 | $0.46 | $3,005.70 |
DisclosureSEC source: 0001654954-17-011773 · section16.xml · nonDerivative · entry 1 BLANCK RONALD R · CIK 0001252491 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,624 Read SEC document |
| November 14, 2017 Filed Nov 20, 2017 17:20 UTC | TENAX THERAPEUTICS, INC. TENX · Entity 979 | SaleCommon Stock | 12,950 | $0.39 | $5,050.50 |
DisclosureSEC source: 0001654954-17-010896 · section16.xml · nonDerivative · entry 1 BLANCK RONALD R · CIK 0001252491 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,149 Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.